Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 7/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 5/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593165 | 0.87 | MAPT (0.46) | ACACBMAPTESR2JAK1NR1H2 | |
| SCHEMBL21593215 | 0.77 | NR1H2 (0.51) | ACACBMAPTESR2JAK1NR1H2 | |
| SCHEMBL21593127 | 0.75 | MAPT (0.44) | ACACBMAPTESR2NR1H2GCK | |
| SCHEMBL25156610 | 0.74 | ESR2 (0.46) | ACACBMAPTESR2NR1H2 | |
| SCHEMBL29883147 | 0.73 | ESR2 (0.55) | ACACBMAPTESR2NR1H2MAP3K5 | |
| SCHEMBL2679894 | 0.73 | ESR2 (0.55) | ACACBMAPTESR2NR1H2MAP3K5 | |
| SCHEMBL25156295 | 0.73 | MAPT (0.51) | ACACBMAPTESR2NR1H2GRAMD1A | |
| SCHEMBL13226239 | 0.72 | ESR2 (0.63) | ACACBMAPTESR2NR1H2MAP3K5 | |
| SCHEMBL13226346 | 0.72 | MAPT (0.50) | ACACBMAPTESR2NR1H2GCK | |
| SCHEMBL21593208 | 0.71 | NR1H2 (0.56) | MAPTESR2JAK1NR1H2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ACACB 2494/4885MAPT 3057/4885ESR2 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.